Project expansion designates target-based Development Programme

A neuroscience collaboration with Bristol Myers Squibb that has achieved an expansion of portfolio with two additional drug discovery projects and designated a target-based programme for further development, has triggered payments of US$ 26 million to Evotec SE (Hamburg, Germany).

Initiated in December 2016 with the goal of identifying disease-modifying treatments the partnership has leveraged Evotec’s precision medicine technologies for modality-agnostic drug discovery and development. A first programme originating from the collaboration, EVT8683, was in-licensed by Bristol Myers Squibb in September 2021, following the successful filing of an IND application with the FDA. 

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, said: “We are delighted to see that after six years our neuroscience collaboration with Bristol Myers Squibb continues to be highly productive across its entire value chain. This is a testament to the scientific excellence and dedication of the teams at Evotec and Bristol Myers Squibb. We are confident that the growing pipeline of promising development candidates will yield transformative therapeutic options for patients living with neurodegenerative conditions.”

More information online